title: Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.
abstract: OBJECTIVE
  It was aimed to monitor early treatment response of Sunitinib in U87MG models mimicking glioblastoma multiforme by longitudinal (18)F-FLT microPET/CT imaging in this study.
  
  
  METHODS
  U87MG tumor mice were intragastrically injected with Sunitinib at a dose of 80 mg/kg for consecutive 7 days. (18)F-FLT microPET/CT scans were acquired on days 0, 1, 3, 7, and 13 after therapy. Tumor sizes and body weight were measured. Tumor samples were collected for immunohistochemical analysis of proliferation and microvessel density (MVD) with anti-Ki67 and anti-CD31, respectively.
  
  
  RESULTS
  The uptake ratios of tumor to the contralateral muscle (T/M) of (18)F-FLT in the Sunitinib group decreased from baseline to day 3 (T/M0 = 2.98 ± 0.33; T/M3 = 2.23 ± 0.36; P < 0.001), reached the bottom on day 7 (T/M7 = 1.96 ± 0.35; P < 0.001), and then recovered on day 13. The T/M of (18)F-FLT uptake in the control group remained around 3.0. There was no difference for the tumor size between both groups until day 11. (18)F-FLT uptakes of tumor were correlated with Ki67 staining index and MVD.
  
  
  CONCLUSIONS
  Early therapy response to Sunitinib could be predicted via (18)F-FLT PET, which will contribute to monitoring antiangiogenesis treatment.
authors.affiliation: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China ; Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
authors.forename: Xiao
authors.identifier: 0000-0002-4196-6691
authors.initials: X
authors.lastname: Bao
authors.affiliation: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China ; Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
authors.forename: Ming-Wei
authors.initials: MW
authors.lastname: Wang
authors.affiliation: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China ; Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
authors.forename: Yong-Ping
authors.initials: YP
authors.lastname: Zhang
authors.affiliation: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China ; Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
authors.forename: Ying-Jian
authors.initials: YJ
authors.lastname: Zhang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D045744:Cell Line, Tumor; D015224:Dideoxynucleosides; D016903:Drug Monitoring; D055088:Early Detection of Cancer / Q000379:methods; D005260:Female; D005909:Glioblastoma / Q000175:diagnosis* / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D011758:Pyrroles / Q000008:administration & dosage*; D019275:Radiopharmaceuticals; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D015224:Dideoxynucleosides; D007211:Indoles; D011758:Pyrroles; D019275:Radiopharmaceuticals; C002854:alovudine; D000077210:Sunitinib